The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer.
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer.
复制标题
DOI：
10.1007/s10147-022-02272-z
复制
发表时间：
2023-03
影响因子：
3.3
通讯作者：
中科院分区：
文献类型：
--
作者：
很少有研究分析全身炎症标志物在早期卵巢癌中的预后作用。本研究的主要终点是评估基线炎症标志物对早期卵巢癌预后的影响。次要终点是比较炎症标志物与标准风险因素的无病生存期（DFS），并将其与BRCA突变状态相关联。回顾性、单中心、观察性研究。纳入了2012年10月至2019年12月期间接受初次手术的FIGO I-II期和IIIA 1期上皮性卵巢癌患者。卵巢癌手术前，根据全血细胞计数和凝血试验结果评估炎症标志物。使用受试者操作特征曲线来确定DFS分析的不同基线炎症生物标志物的最佳截止值。 359例患者被纳入研究期间。基线嗜中性粒细胞-淋巴细胞比值（NLR）≥ 3和全身免疫炎症指数基线SII ≥ 1000与较差的3年DFS相关，基线SII ≥ 1000与较差的3年OS相关。与SII <1000和NLR < 3相比，SII ≥ 1000和NLR ≥ 3的BRCA突变患者的DFS显著较差。FIGO分期> I是复发风险较高的唯一独立危险因素。SII ≥ 1000和NLR ≥ 3与3年无病生存率相关，SII ≥ 1000与3年生存率相关，炎症标志物水平较高的BRCA突变患者亚组（SII ≥ 1000和NLR ≥ 3）与3年无病生存率相关。这些发现可能有助于设计个性化治疗和更密集的监测。在线版本包含补充材料，可通过10.1007/s10147-022-02272-z获得。
Few studies analyzed the prognostic role of systemic inflammatory markers in early-stage ovarian cancer. The primary endpoint of the present study was to assess the prognostic impact of baseline inflammatory markers in early-stage ovarian cancer. The secondary endpoints were to compare the disease-free survival (DFS) of inflammatory markers with standard risk factors and to correlate these with BRCA mutational status. Retrospective, single-center, observational study. Patients with FIGO-stage I–II and IIIA1 epithelial ovarian cancer undergoing primary surgery between 10/2012 and 12/2019 were included. Inflammatory markers were evaluated on the results of the complete blood count and coagulation tests, performed before ovarian cancer surgery. The Receiver Operating Characteristic curve was used to determine the optimal cut-off value of different baseline inflammatory biomarkers for the DFS analysis. Three hundred fifty-nine patients were included in the study period. Baseline neutrophil–lymphocyte ratio (NLR) ≥ 3 and systemic immune inflammation index (SII, defined as platelet x neutrophil–lymphocyte ratio) ≥ 1000 were associated with worse 3 year DFS and baseline SII ≥ 1000 was associated with worse 3 year OS. BRCA-mutated patients with SII ≥ 1000 and with NLR ≥ 3 had significantly worse DFS compared to SII < 1000 and with NLR < 3. FIGO stage > I was the only independent risk factor for higher risk of recurrence. SII ≥ 1000 and NLR ≥ 3 were associated with worse 3 year DFS and SII ≥ 1000 was associated with worse 3 year OS. The subgroups of BRCA-mutated patients with higher inflammation markers (SII ≥ 1000 and NLR ≥ 3) were associated with worse DFS. These findings might be helpful to design personalized treatment and more intensive surveillance. The online version contains supplementary material available at 10.1007/s10147-022-02272-z.